Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | TLR8 | Q9NR97 | 4/20 | 0.47 |
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.47 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.36 |
| ▸ | DHFR | P00374 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12495474 | 0.86 | SMN1; SMN2 (0.46) | NPSR1TLR8TLR7NUDT1KDM4E | |
| SCHEMBL9287308 | 0.84 | TLR8 (0.55) | TLR8TLR7NUDT1MAPK1KDM4E | |
| SCHEMBL8515321 | 0.83 | NPSR1 (0.47) | NPSR1TLR8TLR7KDM4EHPGD | |
| SCHEMBL6416413 | 0.82 | TLR8 (0.56) | NPSR1TLR8TLR7 | |
| SCHEMBL9203920 | 0.81 | NPSR1 (0.49) | NPSR1TLR8TLR7NUDT1KDM4E | |
| SCHEMBL15508400 | 0.81 | NPSR1 (0.49) | NPSR1TLR8TLR7NUDT1KDM4E | |
| SCHEMBL4986988 | 0.79 | TLR8 (0.55) | NPSR1TLR8TLR7MAPTL3MBTL1 | |
| SCHEMBL6419045 | 0.79 | TLR8 (0.55) | NPSR1TLR8TLR7MAPTL3MBTL1 | |
| SCHEMBL15201046 | 0.77 | CYP1A2 (0.36) | NPSR1TLR8TLR7KDM4EHPGD | |
| SCHEMBL857094 | 0.77 | CYP1A2 (0.36) | NPSR1TLR8TLR7KDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140107100-A1 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture | EXELIXIS, INC. (US) | 2014-04-17 | — | — | US | disclosed |
| US-20140107100-A1 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture | EXELIXIS, INC. (US) | 2014-04-17 | — | — | US | disclosed |
| WO-2012071511-A1 | BENZOXAZEPINES AS INHIBITORS OF MTOR AND METHODS OF THEIR USE AND MANUFACTURE | EXELIXIS, INC. (US) | 2012-05-31 | — | — | WO | disclosed |
| EP-2264010-A1 | Hetarylamidines | Bayer CropScience AG (DE) | 2010-12-22 | — | — | EP | disclosed |
| US-6951866-B2 | Bicyclic pyrimidine compounds and therapeutic use thereof | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2005-10-04 | — | — | US | disclosed |
| WO-2004074278-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2004-09-02 | — | — | WO | disclosed |
| EP-1110951-B1 | PYRIMIDINE DERIVATIVES | SUMITOMO PHARMA (JP) | 2004-05-19 | — | — | EP | disclosed |
| US-20030105323-A1 | Pyrimidine derivative | SUMITOMO PHARMACEUTICALS COMPANY LIMITED | 2003-06-05 | — | — | US | disclosed |
| US-6458798-B1 | HAS AN INHIBITORY ACTIVITY OF PRODUCTION OF TH2 TYPE CYTOKINES SUCH AS IL-4, IL-5, ETC., AND IS USEFUL AS AN THERAPEUTIC AGENT FOR ALLERGIC DISEASES, AUTOIMMUNE DISEASES SUCH AS SYSTEMIC LUPUS ERYTHEMATHOSUS, ETC., AND ACQUIRED | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2002-10-01 | — | — | US | disclosed |
| EP-1110951-A1 | PYRIMIDINE DERIVATIVES | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2001-06-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140107100-A1 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture | MTOR, RICTOR, PIK3CA | NPSR1 1460/4885TLR8 3895/4885TLR7 2591/4885 |
| US-20030105323-A1 | Pyrimidine derivative | IL5, IL4, IL15 | NPSR1 1358/4885TLR8 209/4885TLR7 97/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.